DSCs ‘promising’ for severe acute GVHD

Human placenta
Photo by Jeremy Kemp
Placenta-derived decidua stromal cells (DSCs) can treat severe acute graft-versus-host disease (GVHD), according to a small study. When given in the optimal way, DSCs produced GVHD responses in all patients, and the 1-year survival rate was 76%. Steroid-refractory (SR) patients who received DSCs had superior 1-year survival rates compared to SR historical controls and SR patients who received mesenchymal stem cells (MSCs). [Read Article]

Clopidogrel proves noninferior to Plavix

Prescription pills
Photo courtesy of
American Heart Association
Generic clopidogrel is noninferior to the brand-name antiplatelet drug Plavix, according to research published in Circulation: Cardiovascular Quality and Outcomes. When a Canadian health system switched from prescribing Plavix to generic clopidogrel, patients with acute coronary syndrome (ACS) were no more likely to die or experience ACS recurrence within a year. In addition, there were no significant differences between the Plavix and clopidogrel groups in the percentage of patients who were hospitalized for any reason, had a stroke or transient ischemic attack, or experienced bleeding. [Read Article]

Reversal agent exhibits efficacy in patients with major bleeding

Apixaban (Eliquis)
Photo from Pfizer/
Bristol Myers Squibb
Interim trial results suggest andexanet alfa can reverse the activity of factor Xa inhibitors in patients with acute major bleeding. Andexanet alfa reduced median anti-factor Xa inhibitor activity by 91% in patients taking apixaban, 88% in those taking rivaroxaban, and 75% in patients taking enoxaparin. Eleven percent of patients experienced thrombotic events, and 12% of patients died. [Read Article]